On February 28, the NMPA website showed that soscemirase sulfate tablets submitted by Hangyu Pharmaceutical, a subsidiary of Jemincare, had been approved for marketing for adult patients with advanced non-small cell lung cancer harboring KRAS G12C mutation who have received at least one prior systemic therapy. This indication had previously been included in the priority review pathway.
Soscemirase sulfate tablets (JMKX001899, formerly known as somelacib sulfate tablets) are a KRAS inhibitor independently developed by the small-molecule innovation center of Shanghai Jiyu under Jemincare. Preclinical data showed that compared with other products against the same target, soscemirase has stronger brain penetration and lacks cardiac toxicity and drug-drug interaction risk.
The drug first filed for clinical trials in China in October 2021 and was first publicly disclosed for clinical development in the United States in 2022. In addition to NSCLC, for which it has now been approved in China and is in Phase I in the United States, soscemirase sulfate tablets have also been expanded into other indications including colorectal cancer and pancreatic cancer, both in Phase I in the United States.
On November 30, 2021, Jemincare Group announced that its subsidiary Shanghai Jiyu had entered into an exclusive license agreement with Genfleet International, granting exclusive rights outside Greater China for the development, manufacturing, and commercialization of the KRAS inhibitor soscemirase sulfate tablets. Related rights within Greater China remain with Jemincare.
Phase II clinical data presented at ASCO 2025 for soscemirase sulfate tablets in patients with advanced NSCLC carrying KRAS G12C mutation showed the following:
As of November 3, 2024, the median follow-up was 6.8 months. The independently reviewed confirmed objective response rate was 52.4%, the median time to response was 1.4 months, and the disease control rate was 87.6%.
The median progression-free survival was 7.2 months, while the median duration of response and median overall survival had not yet been reached.
A total of 138 patients, or 95.2%, reported treatment-related adverse events, among whom 58 patients, or 40.0%, experienced Grade 3 to 4 treatment-related adverse events. No fatal treatment-related adverse events were reported.
According to the Insight database, there are more than 70 KRAS G12C pipelines in development worldwide. Before this approval, five products had already been approved: garsorasib from InventisBio/CT Tianqing, fulzerasib from GenHouse/Innovent, adagrasib from Bristol Myers Squibb/Zai Lab, sotorasib from Amgen, and glecirasib from Jacobio/Allist. With the approval of soscemirase sulfate tablets from Jemincare, it becomes the sixth approved KRAS G12C inhibitor globally.
Among domestic products, in addition to the newly approved soscemirase sulfate tablets, three KRAS G12C inhibitors, namely garsorasib, fulzerasib, and glecirasib, have all entered the latest National Reimbursement Drug List and are now competing head-to-head in non-small cell lung cancer.
Besides the products already approved, there are 42 domestic KRAS G12C inhibitors still in development, including 15 that have entered the clinical stage. Among them, HJ891 from Huajian Future is progressing fastest and has already started Phase III clinical trials.